



# CERTIFICATE OF ANALYSIS




## Product Details

Product name:	Anti-ERBB2 / HER2 / CD340 Reference Antibody (trastuzumab)	Lot.No.:	
Target:	ERBB2 / HER2 / CD340	Catalog:	CHA053
Target Accession:	P04626	Concentration :	1 mg/mL
Clonality:	Monoclonal	Isotype:	IgG1
Reactivity:	Human	Molecular Weight (kDa) :	150 kDa
Application:	FCM, WB, IHC, In Vivo, ELISA, Function: ADCC	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0   Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A


# Data

## Purity: SDS-PAGE




Anti- Human HER2 ( Trastuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

## Purity: SEC-HPLC




The purity of Anti- Human HER2 ( Trastuzumab) is more than 95%, determined by SEC-HPLC.

## Bioactivity: ELISA



Immobilized human HER2 (His Tag, 2µg/mL) can bind to Anti- Human HER2 (Trastuzumab) with an EC50 of 0.005735 ug/mL.


## Bioactivity: FACS



BT474 cells were stained with Anti- Human HER2 ( Trastuzumab) , with isotype and secondary-only controls. Flow analysis showed specific binding of the antibody, with an EC50 of 0.3024 ug/mL.


The products are for research use only. Not for use in diagnostic procedures.

## Bioactivity: FACS




KBR3 cells were stained with Anti- Human HER2 ( Trastuzumab ) , with isotype and secondary-only controls. Flow analysis showed specific binding of the antibody, with an EC50 of 0.6095 µg/mL.

## Bioactivity: FACS



MCF-7 cells were stained with Anti- Human HER2 ( Trastuzumab ) , with isotype and secondary-only controls. Flow analysis showed specific binding of the antibody, with an EC50 of 0.1000 µg/mL.

## Research in vivo



Anti- Human HER2 ( Trastuzumab ) inhibited the tumor growth of BT474 on NCG mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 88.5% at 10 mpk at D35.

The products are for research use only. Not for use in diagnostic procedures.